VERACYTE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
VERACYTE, INC. (VCYT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $18.66 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $2.85, a 12.84% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $3.27, a 11.38% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $3.69.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $18.66, a 14.90% increase from fiscal 2024.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $16.24, a 55.11% increase from fiscal 2023.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $10.47, a 0.10% increase from fiscal 2022.
- VERACYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $10.46, a 18.79% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $18.66 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $16.24 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $10.47 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $10.46 10-K · filed 2023-03-01 | |||
| 2021-12-31 | $12.88 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $8.67 10-K · filed 2021-02-22 | |||
| 2019-12-31 | $7.77 10-K · filed 2020-02-25 | |||
| 2018-12-31 | $4.71 10-K · filed 2019-02-25 | |||
| 2017-12-31 | $5.13 10-K · filed 2018-02-27 | |||
| 2016-12-31 | $2.53 10-K · filed 2017-03-01 | |||
| 2016-09-30 | $2.50 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $2.50 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $2.85 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $2.85 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $3.04 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $2.99 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $3.27 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | $1.68 10-K · filed 2015-03-25 | |||
| 2014-09-30 | $1.59 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $1.87 10-Q · filed 2014-08-14 | |||
| 2014-03-31 | $3.69 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $1.46 10-K · filed 2015-03-25 | |||
| 2013-09-30 | $1.46 10-Q · filed 2013-11-25 | |||
| 2012-12-31 | $1.05 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |